Vaccine-induced thrombosis and thrombocytopenia (VITT) in Ireland: A review of cases and current practices

Q4 Medicine Thrombosis Update Pub Date : 2021-12-01 DOI:10.1016/j.tru.2021.100086

D. Swan , H. Enright , R. Desmond , G. Le , E. El Hassadi , B. Hennessy , F. Lynott , D. O'Keeffe , M. Crowley , L. Smyth , K. Perera , C. Jennings , F. Ni Ainle , J. Coll , K. Ryan , J. O'Donnell , M. Lavin , N. O'Connell

{"title":"Vaccine-induced thrombosis and thrombocytopenia (VITT) in Ireland: A review of cases and current practices","authors":"D. Swan , H. Enright , R. Desmond , G. Le , E. El Hassadi , B. Hennessy , F. Lynott , D. O'Keeffe , M. Crowley , L. Smyth , K. Perera , C. Jennings , F. Ni Ainle , J. Coll , K. Ryan , J. O'Donnell , M. Lavin , N. O'Connell","doi":"10.1016/j.tru.2021.100086","DOIUrl":null,"url":null,"abstract":"<div><p>Since the beginning of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2) virus pandemic, several highly effective and safe vaccines have been produced at remarkable speed. Following global implementation of vaccination programmes, cases of thrombosis with thrombocytopenia following administration of adenoviral vector-based vaccines started being reported.</p><p>In this review we discuss the known pathogenesis and epidemiology of so-called vaccine induced thrombocytopenia and thrombosis (VITT). We consider the available guidelines, diagnostic laboratory tests and management options for these patients. Finally, we discuss important unanswered questions and areas for future research in this novel pathoclinical entity.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666572721000559/pdfft?md5=053191992e553c408301f6d087c4289b&pid=1-s2.0-S2666572721000559-main.pdf","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thrombosis Update","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666572721000559","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 5

Abstract

Since the beginning of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2) virus pandemic, several highly effective and safe vaccines have been produced at remarkable speed. Following global implementation of vaccination programmes, cases of thrombosis with thrombocytopenia following administration of adenoviral vector-based vaccines started being reported.

In this review we discuss the known pathogenesis and epidemiology of so-called vaccine induced thrombocytopenia and thrombosis (VITT). We consider the available guidelines, diagnostic laboratory tests and management options for these patients. Finally, we discuss important unanswered questions and areas for future research in this novel pathoclinical entity.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

爱尔兰疫苗引起的血栓和血小板减少症(VITT):对病例和当前做法的回顾

自严重急性呼吸综合征冠状病毒-2 (SARS - CoV-2)病毒大流行开始以来，已以惊人的速度生产出几种高效安全的疫苗。在全球实施疫苗接种规划之后，开始报告在接种基于腺病毒载体的疫苗后发生血栓形成伴血小板减少的病例。在这篇综述中，我们讨论了所谓的疫苗诱导的血小板减少和血栓形成(VITT)的已知发病机制和流行病学。我们考虑这些患者可用的指南、诊断实验室检查和管理方案。最后，我们讨论了这一新型病理临床实体的重要未解问题和未来研究的领域。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊